Increasing Prevalence of Fanconi Anemia Coupled with Innovation in Treatment, Heating the Global Fanconi Anemia Drug Market

The global fanconi anemia drug market is anticipated to grow at a considerable CAGR of 5.1% during the forecast period (2022-2028). Fanconi anemia is an extremely rare type of anemia, according to the National Center for Biotechnology Information (NCBI) in January 2022, Fanconi anemia affects an average of 1 out of every 136000 babies, ranging from 1 in 100000 to 250000 infants. Additionally, half of the individuals are diagnosed before the age of ten, with the remaining 10% diagnosed as adults. Furthermore, those of Ashkenazi Jewish heritage, the Roma community of Spain, and black South Africans are more likely to suffer from the disease. As a result, the rising prevalence of fanconi anemia is driving up demand for fanconi anemia medications, which is propelling the market forward. 

Browse the full report description “Global Fanconi Anemia Drug Market Size, Share & Trends Analysis Report By Type (Eltrombopag Olamine, EXG-34217, and Fancalen), and By Application (Hospital & Clinic and Laboratories) Forecast Period (2022-2028)” at https://www.omrglobal.com/industry-reports/fanconi-anemia-drug-market

Moreover, the market is growing due to increased awareness of fanconi anemia and blood disorders, along with a spike in public and private sector initiatives to combat bone marrow diseases. Furthermore, in the forecast period, market players are providing effective novel medications and treatments. For instance, in June 2020, Elixigen Therapeutics, Inc. received FDA approval for EXG34217, EXG34217 is an autologous cell treatment that leverages Elixirgen Therapeutics' unique ZSCAN4 technology to lengthen the telomeres of patients with telomere biology abnormalities and bone marrow failure. Additionally, the company will continue its Phase I/II, open-label, single-center clinical trial to examine the safety and tolerability of EXG34217. 

Market Coverage

• The market number available for – 2021-2028
• Base year- 2021
• Forecast period- 2022-2028

Segment Covered- 

• By Type
• By Application

Regions Covered-

• North America
• Europe
• Asia-Pacific
• Rest of the World

Competitive Landscape- including include Abeona Therapeutics Inc., Genethon SA. Novartis AG, Elixigren Therapeutics, Inc. and others.

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• How COVID-19 impacted the market?

o Deviation from the pre-COVID-19 forecast

o Most affected region and segment

• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Fanconi Anemia Drug Market Report Segment

By Type

• Eltrombopag Olamine
• EXG-34217
• Fancalen

By Application

• Hospital & Clinic
• Laboratories

Global Fanconi Anemia Drug Market Report Segment by Region

North America

• US
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Rest of Europe 

Asia-Pacific

• China
• India
• Japan
• South Korea
• Rest of Asia-Pacific 

Rest of the World

• Latin America 
• Middle East & Africa